BeOne Medicines AG (NASDAQ:ONC) is one of them 12 Best Stocks to Buy and Hold for the Next 2 Years.
On February 26, BeOne Medicines AG (NASDAQ:ONC) reported total global revenue of $1.5 billion for the fourth quarter of 2025 and $5.3 billion for 2026, up 33% and 40% from the prior quarter and year-ago period, respectively. Brookinsa, the company’s lymphoma and leukemia treatments, had revenue of $1.1 billion and $3.9 billion for the fourth quarter and full year, respectively, up 38% and 49% from the prior-year period.
After the earnings report, on February 27, Truist Securities raised their price target on BeOne Medicines AG (NASDAQ:ONC) from $400 to $412 while maintaining a buy rating on the stock. Truist adjusted its price target after incorporating insights from quarterly results, fiscal 2026 guidance, and post-earnings discussions with the company.
Truist Securities noted BeOne Medicines AG’s (NASDAQ:ONC) fiscal 2026 revenue guidance of $6.2 billion to $6.4 billion, roughly bracketing consensus estimates of $6.4 billion and causing additional pressure on shares. The analyst said its current outlook on BeOne Pharmaceuticals AG (NASDAQ:ONC) suggests healthy growth for Brookinsa even without any major label expansion.
Grail Inc. Gallery Cancer Test Screening Kit. Image from the Grill website
BeOne Medicines AG (NASDAQ:ONC) is a global oncology company that discovers and develops new treatments that are more affordable and accessible to cancer patients worldwide.
While we acknowledge ONC’s potential as an investment, we believe some AI stocks offer higher potential and less risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: 13 Hot Stocks to Buy with High Upside Potential and 10 Best High Upside Material Stocks to Buy
Disclosure: None. Follow the inside port on Google News.
